Alaunos Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $7.61M
- P/E (TTM)
- –
- Dividend yield
- –
About Alaunos Therapeutics
Pharmaceutical Preparations, SIC 2834
Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical enterprise concentrating on the discovery and development of orally administered small-molecule treatments for obesity and metabolic conditions, including metabolic dysfunction-associated steatotic liver disease. The company's lead therapeutic candidate, ALN1003, utilizes a differentiated, non-hormonal, and non-incretin mechanism of action intended to provide an alternative or complementary option to hormone-based incretin therapies. Alaunos previously operated as a clinical-stage oncology biotechnology firm focused on developing adoptive T-cell receptor engineered cell therapies before pivoting away from that portfolio.
The company operates with a single full-time employee and relies on third-party consultants, advisors, and contract development and manufacturing organizations to handle administrative functions, research, and drug substance production. Alaunos conducts its corporate operations from its principal executive offices located in Fort Lauderdale, Florida.
Summary of the business section of Alaunos Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alaunos Therapeutics, Inc.
- Founded
- 1998
- Headquarters
- Fort Lauderdale, FL
- Address
- 501 E Las Olas Blvd, Suite 300 33301
- Phone
- (346) 355-4099
- Website
- alaunos.com
- Employees
- 1, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- TCRT
- Exchange
- Nasdaq
- IPO date
- Aug 24, 2005
- Shares outstanding
- 3M, Aug 14, 2026
- Public float
- $9.61M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Aug 14, 2024; 1-for-10 reverse, Jul 18, 2024; 1-for-15 reverse, Apr 1, 2024; 1-for-15 reverse, Feb 1, 2024
- SEC CIK
- 1107421
- CUSIP
- 98973P309
- ISIN
- US98973P3091
- EIN
- 84-1475642
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dale Curtis Hogue Jr. | See Remarks, Director | – |
| Holger Weis | CEO | 44,683 |
| Ferdinand Groenewald | Vice President of Finance | 10,775 |
| Melinda Lackey | Legal & Administration | – |
| Robert W. Postma | Director | 121,049 |
| Jaime Vieser | Director | 63,245 |
| Michael Allen Jerman | Director | 23,759 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Mrhogue | $308.34K | $354.48K | $296.34K | $4 | – |
| FY2023 Mrboyle | $1.72M | $1.46M | $665.71K | $3 | – |
| FY2022 Mrboyle | $1.79M | $1.84M | $856.93K | $6 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we had one full-time employee and no part-time employees.”
Corporate history
Events identified from SEC filings